Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long Term Efficacy of Dexamethasone Intravitreal Implant (Ozurdex) in Treatment of Recurrent VKH Uveitis

Trial Profile

Long Term Efficacy of Dexamethasone Intravitreal Implant (Ozurdex) in Treatment of Recurrent VKH Uveitis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Posterior uveitis
  • Focus Therapeutic Use

Most Recent Events

  • 24 Nov 2019 Status changed from recruiting to completed.
  • 31 Aug 2019 Planned End Date changed from 1 Jul 2020 to 1 Oct 2019.
  • 31 Aug 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Oct 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top